CMTx Biotech is a clinical-stage biopharmaceutical company that is developing an orally-administered small molecule for the treatment of sepsis patients at risk of Acute Respiratory Distress Syndrome (ARDS) and/or Multiple Organ Dysfunction Syndrome (MODS), including those infected with SARS-CoV-2 (COVID-19). The company is currently preparing to advance into a Phase II clinical trial to demonstrate the safety and efficacy of our lead drug candidate. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of rare diseases.